九典制药：PDX-04获药物临床试验批准通知书

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of a new drug, PDX-04, aimed at treating acute gout attacks, marking a significant development in its product pipeline [1] Group 1: Drug Development - PDX-04 is classified as a chemical drug of category 2.2 and is intended for use as a topical formulation [1] - The drug provides a new treatment option for patients suffering from acute gout attacks, a condition for which there are currently no similar products in clinical trials domestically or internationally [1] Group 2: Financial Impact - The approval for clinical trials of PDX-04 is not expected to have a significant impact on the company's financial status or operating performance [1]